PIK3CA c.1215C>A ;(p.S405=)

Variant ID: 3-178927452-C-A

NM_006218.2(PIK3CA):c.1215C>A;(p.S405=)

This variant was identified in 5 publications

View GRCh38 version.




Publications:


Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.

Nature Communications
Kis, Olena O; Kaedbey, Rayan R; Chow, Signy S; Danesh, Arnavaz A; Dowar, Mark M; Li, Tiantian T; Li, Zhihua Z; Liu, Jessica J; Mansour, Mark M; Masih-Khan, Esther E; Zhang, Tong T; Bratman, Scott V SV; Oza, Amit M AM; Kamel-Reid, Suzanne S; Trudel, Suzanne S; Pugh, Trevor J TJ
Publication Date: 2017-05-11

Variant appearance in text: PI3K: 1215C>A; S405S
PubMed Link: 28492226
Variant Present in the following documents:
  • ncomms15086-s3.xlsx, sheet 1
View BVdb publication page



Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.

Molecular Cancer Therapeutics
Ganesan, Prasanth P; Moulder, Stacy S; Lee, J Jack JJ; Janku, Filip F; Valero, Vicente V; Zinner, Ralph G RG; Naing, Aung A; Fu, Siqing S; Tsimberidou, Apostolia M AM; Hong, David D; Stephen, Bettzy B; Stephens, Philip P; Yelensky, Roman R; Meric-Bernstam, Funda F; Kurzrock, Razelle R; Wheler, Jennifer J JJ
Publication Date: 2014-12

Variant appearance in text: PIK3CA: S405S
PubMed Link: 25253784
Variant Present in the following documents:
  • Main text
View BVdb publication page



Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

Cell Reports
Janku, Filip F; Hong, David S DS; Fu, Siqing S; Piha-Paul, Sarina A SA; Naing, Aung A; Falchook, Gerald S GS; Tsimberidou, Apostolia M AM; Stepanek, Vanda M VM; Moulder, Stacy L SL; Lee, J Jack JJ; Luthra, Rajyalakshmi R; Zinner, Ralph G RG; Broaddus, Russell R RR; Wheler, Jennifer J JJ; Kurzrock, Razelle R
Publication Date: 2014-01-30

Variant appearance in text: PIK3CA: S405S
PubMed Link: 24440717
Variant Present in the following documents:
  • Main text
View BVdb publication page



Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.

Molecular Cancer Therapeutics
Ganesan, Prasanth P; Janku, Filip F; Naing, Aung A; Hong, David S DS; Tsimberidou, Apostolia M AM; Falchook, Gerald S GS; Wheler, Jennifer J JJ; Piha-Paul, Sarina A SA; Fu, Siqing S; Stepanek, Vanda M VM; Lee, J Jack JJ; Luthra, Rajyalakshmi R; Overman, Michael J MJ; Kopetz, E Scott ES; Wolff, Robert A RA; Kurzrock, Razelle R
Publication Date: 2013-12

Variant appearance in text: PIK3CA: S405S
PubMed Link: 24092809
Variant Present in the following documents:
  • Main text
View BVdb publication page



PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Cancer Research
Janku, Filip F; Wheler, Jennifer J JJ; Naing, Aung A; Falchook, Gerald S GS; Hong, David S DS; Stepanek, Vanda M VM; Fu, Siqing S; Piha-Paul, Sarina A SA; Lee, J Jack JJ; Luthra, Rajyalakshmi R; Tsimberidou, Apostolia M AM; Kurzrock, Razelle R
Publication Date: 2013-01-01

Variant appearance in text: PIK3CA: S405S
PubMed Link: 23066039
Variant Present in the following documents:
  • Main text
View BVdb publication page